Analysts Anticipate Galectin Therapeutics Inc. (NASDAQ:GALT) to Announce -$0.09 EPS

Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to announce earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Galectin Therapeutics’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.07). Galectin Therapeutics posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 28.6%. The firm is expected to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.47) per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.51) to ($0.41). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Friday, August 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04.

Separately, Zacks Investment Research cut Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 14th.

In other news, major shareholder Fund L.P. 10X sold 17,000 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $3.73, for a total value of $63,410.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 40.70% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of Galectin Therapeutics by 243.4% in the 2nd quarter. BlackRock Inc. now owns 2,045,111 shares of the company’s stock valued at $8,486,000 after acquiring an additional 1,449,610 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Galectin Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,734,324 shares of the company’s stock valued at $7,197,000 after acquiring an additional 125,092 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Galectin Therapeutics by 16.5% in the 2nd quarter. Advisor Group Inc. now owns 807,175 shares of the company’s stock valued at $3,350,000 after acquiring an additional 114,586 shares during the last quarter. D.A. Davidson & CO. lifted its stake in shares of Galectin Therapeutics by 4.8% in the 2nd quarter. D.A. Davidson & CO. now owns 790,874 shares of the company’s stock valued at $3,282,000 after acquiring an additional 36,519 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of Galectin Therapeutics by 32.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 232,554 shares of the company’s stock valued at $965,000 after acquiring an additional 56,332 shares during the last quarter. Institutional investors own 14.93% of the company’s stock.

NASDAQ GALT traded up $0.13 on Monday, hitting $3.95. 141,840 shares of the company’s stock were exchanged, compared to its average volume of 338,627. The stock has a 50-day moving average of $3.73 and a 200-day moving average of $3.95. Galectin Therapeutics has a 52 week low of $2.94 and a 52 week high of $6.16. The stock has a market cap of $224.26 million, a price-to-earnings ratio of -10.39 and a beta of 3.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Featured Article: What is the cash asset ratio?

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.